Celltrion, Inc.
068270
Rangering i aksjer
#720
Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the... Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.
Aksjekurs
$146.63
Markedsverdi
$33.44B
Endring (1 dag)
-1.52%
Endring (1 år)
23.60%
Land
KR
Handel Celltrion, Inc. (068270)
Kategori
Healthcare
P/B-forhold for Celltrion, Inc. (068270)
P/B-forhold per October 2026 TTM: 2.53
Ifølge Celltrion, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 2.53. Ved slutten av 2024 hadde selskapet et P/B-forhold på 2.24.
P/B-historikk for Celltrion, Inc. fra 2007 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 2.53 | 9.58% |
| 2025 | 2.31 | 3.13% |
| 2024 | 2.24 | 25.90% |
| 2023 | 1.78 | -63.55% |
| 2022 | 4.89 | -24.18% |
| 2021 | 6.45 | -52.43% |
| 2020 | 13.55 | 69.06% |
| 2019 | 8.02 | -20.22% |
| 2018 | 10.05 | -10.80% |
| 2017 | 11.27 | 91.69% |
| 2016 | 5.88 | 8.71% |
| 2015 | 5.41 | 64.56% |
| 2014 | 3.29 | -11.72% |
| 2013 | 3.72 | 38.97% |
| 2012 | 2.68 | -38.11% |
| 2011 | 4.33 | -1.51% |
| 2010 | 4.39 | -11.37% |
| 2009 | 4.96 | 22.00% |
| 2008 | 4.06 | 544.31% |
| 2007 | 0.63 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.6964 | 164.53% |
US
|
|
| 13.6307 | 438.46% |
US
|
|
| 4.4521 | 75.88% |
AU
|
|
| 4.2241 | 66.87% |
BE
|
|
| 6.3632 | 151.37% |
NL
|
